Tokyo, Japan

Hiroko Inamura


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroko Inamura: Innovator in Pharmaceutical Solutions for Urinary Incontinence

Introduction

Hiroko Inamura is a distinguished inventor based in Tokyo, Japan, known for her significant contributions to the field of pharmaceuticals. With an innovative approach to medical solutions, she has focused on addressing urinary incontinence—a condition that affects millions worldwide.

Latest Patents

Inamura holds a patent for a unique pharmaceutical composition aimed at the prevention and treatment of urinary incontinence. This invention provides a therapeutic agent characterized by the active ingredient 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide or a salt thereof. This novel composition distinguishes itself from conventional drugs, offering new hope for those afflicted by this condition.

Career Highlights

Throughout her career, Hiroko Inamura has collaborated with leading pharmaceutical companies, including Astellas Pharma GmbH and Cytokinetics, Inc. Her work in these esteemed organizations has allowed her to harness her skills and expertise to advance medical technologies and therapeutic interventions.

Collaborations

Inamura has worked alongside notable colleagues such as Shinobu Mori and Yusuke Kajihara. These collaborations have been instrumental in refining her inventions and furthering progress in pharmaceutical research.

Conclusion

Hiroko Inamura stands as a key figure in the realm of innovative pharmaceutical solutions. Her patented invention for urinary incontinence exemplifies her commitment to improving the quality of life for patients. As she continues her work, the potential for new advancements in this field remains promising, reflecting her passion for innovation and dedication to medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…